Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET
Company Participants
Carlo Tanzi - IR
Eric Shaff - CEO
Lisa von Moltke - Chief Medical Officer
Marella Thorell - CFO
Matthew Henn - EVP, Chief Scientific Officer
Teresa Young - EVP, Chief Commercial & Strategy Officer,
Conference Call Participants
Tessa Romero - JPMorgan Chase & Co.
Edward Tenthoff - Piper Sandler
Peyton Bohnsack - TD Cowen
Operator
Good day, and thank you for standing by. At this time, I would like to welcome everyone to Seres Therapeutics Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Dr. Carlo Tanzi, Investor Relations. Please go ahead.
Carlo Tanzi
Thank you, and good morning. Our press release with the company's second quarter 2024 financial results and a business update became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website. The company has also posted an updated corporate presentation to the website.
I'd like to remind you that we are making forward-looking statements, including related to the financial terms, timing and completion of the sale of VOWST assets to Nestle Health Science. The receipt of future payments and the use of proceeds of the transaction, the timing and results of clinical studies and data readouts, development plans and commercial opportunities, operating plans and our future cash runway, our planned strategic focus and other statements, which are not historical fact. Actual results may differ materially.
On today's call with prepared remarks, I'm joined by Eric Shaff, Seres' President and CEO; Marella Thorell, CFO; Dr. Lisa von Moltke, Chief Medical Officer; Dr. Matthew Henn, Chief Scientific Officer; and Dr. Terri Young, Chief Commercial and Strategy Officer.
With that, I'll pass the call to Eric.
Eric Shaff
Thank you, Carlo, and good morning, everyone. Last week, we announced our agreement to sell Seres VOWST assets of commercial rights to Nestle Health Science in exchange for substantial immediate and future financial consideration.
We held a call at that time to review the agreement and the deal terms and to provide a high-level view of our planned corporate strategy to advance our live biotherapeutics drug candidates, which are consortia bacterial strains cultivated from clonal master cell banks and rationally design and optimize target disease-relevant pathways.
Today's call will focus on our SER-155 program, and the clinical data we look forward to obtaining next month and more broadly, our strategy moving forward. Later in the call, we will provide a review of our second quarter financial results.